Aistarfish (Haixin Zhihui)

About Aistarfish (Haixin Zhihui)

Aistarfish (Haixin Zhihui), established in January 2018, operates as an intelligent service platform within the oncology diagnosis and treatment sector. The company has developed a comprehensive tumor-intelligent whole-course management platform aimed at providing affordable and extensive disease case management services.

The firm's offerings are centered around artificial intelligence to support patients throughout their treatment journey, both in hospital and at home. Its main product suite includes a multi-tumor Clinical Decision Support System (CDSS), digital therapy solutions, and support for clinical new drug research and development. Aistarfish also provides out-of-hospital products and services for patients. The company's CSCO AI intelligent decision-making system has received endorsement from the Chinese Society of Clinical Oncology (CSCO), a notable achievement that enhances its credibility within the medical community. This system is designed to empower oncology departments by improving the overall standard of cancer diagnosis and treatment. To date, the system has been launched for several types of cancer, including breast, lung, esophageal, gastric, and colorectal cancer.

The company's business model serves a diverse client base that includes tumor patients, hospital departments, pharmaceutical companies, and government bodies. For patients, the platform offers a space to share and update their cases, connecting them with a large community of fellow patients. For its institutional clients, Aistarfish provides theranostic solutions and clinical trial recruitment services, leveraging the extensive tumor patient database it has established. Since its inception, Aistarfish's services have expanded to over 30 provinces, partnering with more than 600 hospital departments and attracting approximately 100,000 registered patients. The company has secured multiple rounds of funding to support its growth, including Series B, B1, and B2 financing, which have been allocated towards talent acquisition, product development, and research and development.